Oligonucleotide Therapeutics: From Discovery and Development to Patentability
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oligonucleotide Therapeutics: From Discovery and Development to Patentability
Authors
Keywords
-
Journal
Pharmaceutics
Volume 14, Issue 2, Pages 260
Publisher
MDPI AG
Online
2022-01-24
DOI
10.3390/pharmaceutics14020260
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lumasiran: First Approval
- (2021) Lesley J. Scott et al. DRUGS
- Inclisiran: First Approval
- (2021) Yvette N. Lamb DRUGS
- Duchenne muscular dystrophy
- (2021) Dongsheng Duan et al. Nature Reviews Disease Primers
- Casimersen: First Approval
- (2021) Matt Shirley DRUGS
- RNA therapeutics in ophthalmology - translation to clinical trials
- (2021) Aanchal Gupta et al. EXPERIMENTAL EYE RESEARCH
- Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations
- (2021) Kalyan Dulla et al. MOLECULAR THERAPY
- Durable vision improvement after a single treatment with antisense oligonucleotide sepofarsen: a case report
- (2021) Artur V. Cideciyan et al. NATURE MEDICINE
- An oral antisense oligonucleotide for PCSK9 inhibition
- (2021) Peter Gennemark et al. Science Translational Medicine
- Cholesterol-functionalized DNA/RNA heteroduplexes cross the blood–brain barrier and knock down genes in the rodent CNS
- (2021) Tetsuya Nagata et al. NATURE BIOTECHNOLOGY
- The glomerular filtration barrier: a structural target for novel kidney therapies
- (2021) Ilse S. Daehn et al. NATURE REVIEWS DRUG DISCOVERY
- Noncoding RNA therapeutics — challenges and potential solutions
- (2021) Melanie Winkle et al. NATURE REVIEWS DRUG DISCOVERY
- Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection
- (2021) Lung-Yi Mak et al. Viruses-Basel
- BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial
- (2021) Eric J. Lawitz et al. HEPATOLOGY
- Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial
- (2021) Man-Fung Yuen et al. NATURE MEDICINE
- Systemic Brain Delivery of Antisense Oligonucleotides across the Blood-Brain Barrier with a Glucose-Coated Polymeric Nanocarrier
- (2020) Hyun Su Min et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Golodirsen: First Approval
- (2020) Young-A Heo DRUGS
- Givosiran: First Approval
- (2020) Lesley J. Scott DRUGS
- MTL-CEBPA, a small activating RNA therapeutic up-regulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multi-centre, open-label, phase I trial
- (2020) Debashis Sarker et al. CLINICAL CANCER RESEARCH
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Viltolarsen: First Approval
- (2020) Sohita Dhillon DRUGS
- Advances in oligonucleotide drug delivery
- (2020) Thomas C. Roberts et al. NATURE REVIEWS DRUG DISCOVERY
- Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression
- (2020) Kian Huat Lim et al. Nature Communications
- Risdiplam: First Approval
- (2020) Sohita Dhillon DRUGS
- Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome
- (2020) Zhou Han et al. Science Translational Medicine
- Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy
- (2020) Sundee Dees et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Application of Permeation Enhancers in Oral Delivery of Macromolecules: An Update
- (2019) Sam Maher et al. Pharmaceutics
- Therapeutic Antisense Oligonucleotides Are Coming of Age
- (2019) C. Frank Bennett Annual Review of Medicine
- N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
- (2019) Veronica J Alexander et al. EUROPEAN HEART JOURNAL
- Onasemnogene Abeparvovec: First Global Approval
- (2019) Sheridan M. Hoy DRUGS
- Volanesorsen: First Global Approval
- (2019) Julia Paik et al. DRUGS
- Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
- (2019) Maria K. Tsoumpra et al. EBioMedicine
- Metazoan MicroRNAs
- (2018) David P. Bartel CELL
- RNA-Targeted Therapeutics
- (2018) Stanley T. Crooke et al. Cell Metabolism
- GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics
- (2018) Aaron D. Springer et al. Nucleic Acid Therapeutics
- Inotersen: First Global Approval
- (2018) Susan J. Keam DRUGS
- Patisiran: First Global Approval
- (2018) Sheridan M. Hoy DRUGS
- Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives
- (2018) Aikaterini N. Tsouka et al. CURRENT PHARMACEUTICAL DESIGN
- A microRNA-29 mimic (remlarsen) represses extracellular matrix expression and fibroplasia in the skin
- (2018) Corrie L. Gallant-Behm et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Targeted delivery of antisense oligonucleotides to pancreatic β-cells
- (2018) C. Ämmälä et al. Science Advances
- STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial
- (2018) Matthew J. Reilley et al. Journal for ImmunoTherapy of Cancer
- Oligonucleotide therapies for disorders of the nervous system
- (2017) Olga Khorkova et al. NATURE BIOTECHNOLOGY
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice
- (2017) Hichem Tasfaout et al. Nature Communications
- First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
- (2017) Norbert Pfeiffer et al. PLoS One
- Eteplirsen: First Global Approval
- (2016) Yahiya Y. Syed DRUGS
- Antisense rescues babies from killer disease
- (2016) Meredith Wadman SCIENCE
- Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
- (2015) Sotirios Tsimikas et al. LANCET
- Principles of nanoparticle design for overcoming biological barriers to drug delivery
- (2015) Elvin Blanco et al. NATURE BIOTECHNOLOGY
- Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
- (2014) Jayaprakash K. Nair et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Mipomersen Sodium: First Global Approval
- (2013) Philip Hair et al. DRUGS
- Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals
- (2011) Meghan A. Campbell et al. CHEMICAL SOCIETY REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More